Nuo Yu

Dr. Nuo Yu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
XWXin Wang
Xin Wang
XKXiaozheng Kang
Xiaozheng Kang
RZRuixiang Zhang
Ruixiang Zhang
LXLiyan Xue
Liyan Xue
JXJiaqi Xu
Jiaqi Xu
YLYin Li
Yin Li
Purpose: This phase II trial investigated the safety and efficacy of chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and surgery in unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Patients and Methods: Patients with unresectable locally advanced ESCC received radiotherapy (50 Gy/25f, 5 days/week) and nab-paclitaxel (100 mg on day 1/week) plus cisplatin (25 mg/m2 on day 1/week) for 5 weeks, followed by tislelizumab (200 mg on day 1/cycle) plus chemotherapy (nab-paclitaxel 150 mg/m2 and cisplatin 75 mg/m2 on day 2/cycle) for two 21-day cycles. Patients who converted to resectable underwent surgery 2 to 4 weeks afterward. The primary endpoint was a 1-year progression-free survival (PFS) rate. Results: Thirty patients were enrolled and underwent CRT (median follow-up: 21 months), of whom 24 received iCT. Twenty (66.7%) patients achieved resectability (R0: 95.2%; pathologic complete response: 65.0%; major pathologic response: 90.0%). One-year PFS and overall survival (OS) rates were 79.4% and 89.6%, respectively. The R0 resection group exhibited longer PFS (median, not reached vs. 8.4 months; HR = 0.28; 95% confidence interval, 0.08–0.84; P = 0.02) and OS (median, not reached vs. 19.2 months; HR = 0.18; 95% confidence interval, 0.04–0.73; P < 0.01) than the nonsurgery group. Grade 3 to 4 adverse events were observed in 11 (11/30, 36.7%) patients, and immune-related pneumonitis was observed in 5 (5/24, 20.8%) patients. Post-CRT minimal residual disease before surgery was associated with unfavorable PFS and OS. Conclusions: Our study met the primary endpoint. Conversion CRT and subsequent iCT followed by surgery was a promising treatment strategy for unresectable locally advanced ESCC.

3 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NYNuo Yu
Nuo Yu
XGXiaolin Ge
Xiaolin Ge
LZLijing Zuo
Lijing Zuo
YCYing Cao
Ying Cao
PWPeipei Wang
Peipei Wang
XWXin Wang
Xin Wang
Purpose: We constructed a prediction model to predict a 2-year locoregional recurrence based on the clinical features and radiomic features extracted from the machine learning method using computed tomography (CT) before definite chemoradiotherapy (dCRT) in locally advanced esophageal cancer. Patients and methods: A total of 264 patients (156 in Beijing, 87 in Tianjin, and 21 in Jiangsu) were included in this study. All those locally advanced esophageal cancer patients received definite radiotherapy and were randomly divided into five subgroups with a similar number and divided into training groups and validation groups by five cross-validations. The esophageal tumor and extratumoral esophagus were segmented to extract radiomic features from the gross tumor volume (GTV) drawn by radiation therapists before radiotherapy, and six clinical features associated with prognosis were added. T stage, N stage, M stage, total TNM stage, GTV, and GTVnd volume were included to construct a prediction model to predict the 2-year locoregional recurrence of patients after definitive radiotherapy. Results: A total of 264 patients were enrolled from August 2012 to April 2018, with a median age of 62 years and 81% were males. The 2-year locoregional recurrence rate was 52.6%, and the 2-year overall survival rate was 45.6%. About 66% of patients received concurrent chemotherapy. In total, we extracted 786 radiomic features from CT images and the Principal Component Analysis (PCA) method was used to screen out the maximum 30 features. Finally, the Support Vector Machine (SVM) method was used to construct the integrated prediction model combining radiomics and clinical features. In the five training groups for predicting locoregional recurrence, the mean value of C-index was 0.9841 (95%CI, 0.9809–0.9873), and in the five validation groups, the mean value was 0.744 (95%CI, 0.7437–0.7443). Conclusions: The integrated radiomics model could predict the 2-year locoregional recurrence after dCRT. The model showed promising results and could help guide treatment decisions by identifying high-risk patients and enabling strategies to prevent early recurrence.


15 November 2024
Verified
Other
Open access
XWXin Wang
Xin Wang
XKXiaozheng Kang
Xiaozheng Kang
RZRuixiang Zhang
Ruixiang Zhang
LXLiyan Xue
Liyan Xue
JXJiaqi Xu
Jiaqi Xu
YLYin Li
Yin Li
Supplementary Figure 5. Results of univariate analyses for overall survival

15 November 2024
Verified
Other
Open access
XWXin Wang
Xin Wang
XKXiaozheng Kang
Xiaozheng Kang
RZRuixiang Zhang
Ruixiang Zhang
LXLiyan Xue
Liyan Xue
JXJiaqi Xu
Jiaqi Xu
YLYin Li
Yin Li
Supplementary Table 4. Postoperative complications in patients with R0 resection (n=20)

15 November 2024
Verified
Other
Open access
XWXin Wang
Xin Wang
XKXiaozheng Kang
Xiaozheng Kang
RZRuixiang Zhang
Ruixiang Zhang
LXLiyan Xue
Liyan Xue
JXJiaqi Xu
Jiaqi Xu
YLYin Li
Yin Li
Supplementary Table 3. The LRFS and DMFS data for the R0 resection and non-surgery group